Aurora Cannabis Inc.

ACB · NASDAQ

Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.

Follow Add to Watchlist Ask Question

NASDAQ ACB Coverage Bootstrap Cannabis Medical Cannabis Turnaround

Latest ReportMay 13, 2026Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

ACBTurnaround

Clear tags

MatchAny tag All tags

Latest Thesis

Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilution

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Aurora Cannabis Inc.Cannabis (ACB): the medical-cannabis turnaround trying to outrunMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

ReportTypeUpdatedReadActions

Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.NASDAQMay 13, 2026Research reportRead Slides